Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Ventas, Inc. | exhibit991hct093014.htm |
| 8-K - 8-K - Ventas, Inc. | q32014form8-kbodyproformai.htm |
Exhibit 99.2
VENTAS, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
As of and For the Nine Months Ended September 30, 2014 and For the Year Ended December 31, 2013
On June 2, 2014, Ventas, Inc. (“Ventas” or the “Company”) announced that it had entered into a definitive agreement to acquire all of the outstanding shares of American Realty Capital Healthcare Trust, Inc. (“HCT”) in a stock and cash transaction valued at $2.9 billion, or $11.33 per HCT share, including investments expected to be made by HCT prior to completion of the acquisition, substantially all of which have now been completed.
The following unaudited pro forma condensed consolidated financial information sets forth:
• | The historical consolidated financial information of Ventas as of and for the nine months ended September 30, 2014, derived from Ventas’s unaudited consolidated financial statements, and the historical consolidated statement of income information of Ventas for the year ended December 31, 2013, derived from Ventas’s audited consolidated financial statements; |
• | Pro forma adjustments to give effect to Ventas’s 2014 and 2013 acquisitions and other investments, dispositions and significant debt activity (including the August 2014 acquisition of 29 independent living seniors housing communities located in Canada and the April 2014 issuance and sale of $700 million aggregate principal amount of senior notes) on Ventas’s consolidated statements of income for the nine months ended September 30, 2014 and for the year ended December 31, 2013, as if these transactions occurred on January 1, 2013; |
• | The historical consolidated financial information of HCT as of and for the nine months ended September 30, 2014, derived from HCT’s unaudited consolidated financial statements, and the historical consolidated statement of income information of HCT for the year ended December 31, 2013, derived from HCT’s audited consolidated financial statements; |
• | Pro forma adjustments to give effect to HCT’s 2014 and 2013 acquisitions and other investments, dispositions and significant debt activity on HCT’s consolidated statements of income for the nine months ended September 30, 2014 and for the year ended December 31, 2013, as if these transactions occurred on January 1, 2013; |
• | Pro forma adjustments to give effect to Ventas’s acquisition of HCT on Ventas’s consolidated balance sheet as of September 30, 2014, as if the acquisition closed on September 30, 2014; and |
• | Pro forma adjustments to give effect to Ventas’s acquisition of HCT on Ventas’s consolidated statements of income for the nine months ended September 30, 2014 and for the year ended December 31, 2013, as if the acquisition closed on January 1, 2013. |
These unaudited pro forma condensed consolidated financial statements have been prepared for informational purposes only and are based on assumptions and estimates considered appropriate by Ventas’s management; however, they are not necessarily indicative of what Ventas’s consolidated financial condition or results of operations actually would have been assuming the transactions had been consummated as of the dates indicated, nor do they purport to represent Ventas’s consolidated financial position or results of operations for future periods. These unaudited pro forma condensed consolidated financial statements do not include the impact of any synergies that may be achieved in the transactions or any strategies that management may consider in order to continue to efficiently manage Ventas’s operations. This pro forma condensed consolidated financial information should be read in conjunction with:
• | Ventas’s unaudited consolidated financial statements and the related notes thereto as of and for the nine months ended September 30, 2014 included in the Company’s Quarterly Report on Form 10-Q for the quarter then ended, filed with the Securities and Exchange Commission (“SEC”) on October 24, 2014; |
• | Ventas’s audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K for the year then ended, filed with the SEC on February 18, 2014, as amended by Amendment No. 1 to the Company’s Annual Report on Form 10-K/A, filed with the SEC on September 4, 2014; |
• | HCT’s unaudited consolidated financial statements and the related notes thereto as of and for the nine months ended September 30, 2014 included in HCT’s Quarterly Report on Form 10-Q for the quarter then ended, filed with the SEC on October 31, 2014; and |
• | HCT’s audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2013 included in HCT’s Annual Report on Form 10-K for the year then ended, filed with the SEC on February 26, 2014. |
The acquisition of HCT will be accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification Topic 805, Business Combinations. The total purchase price of approximately $2.9 billion will be allocated to the assets ultimately acquired and liabilities ultimately assumed based upon their respective fair values. The allocations of the purchase price reflected in these unaudited pro forma condensed consolidated financial statements have not been finalized and are based upon preliminary estimates of these fair values, which is the best available information at the current time. A final determination of the fair values of the assets acquired and liabilities assumed, which cannot be made prior to the completion of the acquisition, will be based on the actual valuations of the tangible and intangible assets and liabilities that exist as of the date of completion of the acquisition. Consequently, amounts preliminarily allocated to identifiable tangible and intangible assets and liabilities could change significantly from those used in the unaudited pro forma condensed consolidated financial statements and could result in a material change in depreciation and amortization of tangible and intangible assets and liabilities.
The completion of the valuation, the allocation of purchase price, the impact of ongoing integration activities, the timing of completion of the acquisition and other changes in tangible and intangible assets and liabilities that occur prior to completion of the acquisition could cause material differences in the information presented herein.
VENTAS, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
As of September 30, 2014
(In thousands)
Ventas Historical | HCT Historical (A) | HCT Acquisition Adjustments (B) | Total Pro Forma | ||||||||||||||
Assets | |||||||||||||||||
Net real estate investments | $ | 19,421,537 | $ | 2,055,108 | $ | 666,993 | (C) | $ | 22,143,638 | ||||||||
Cash and cash equivalents | 64,595 | 33,452 | — | 98,047 | |||||||||||||
Escrow deposits and restricted cash | 78,746 | 3,135 | — | 81,881 | |||||||||||||
Deferred financing costs, net | 64,898 | 17,735 | (17,735 | ) | (D) | 64,898 | |||||||||||
Other assets | 1,021,389 | 38,907 | 149,205 | (E) | 1,209,501 | ||||||||||||
Total assets | $ | 20,651,165 | $ | 2,148,337 | $ | 798,463 | $ | 23,597,965 | |||||||||
Liabilities and equity | |||||||||||||||||
Liabilities: | |||||||||||||||||
Senior notes payable and other debt | $ | 10,469,106 | $ | 926,843 | $ | 199,601 | (F) | $ | 11,595,550 | ||||||||
Accrued interest | 69,112 | 1,581 | — | 70,693 | |||||||||||||
Accounts payable and other liabilities | 965,240 | 98,072 | (34,849 | ) | (G) | 1,028,463 | |||||||||||
Deferred income taxes | 361,454 | — | — | 361,454 | |||||||||||||
Total liabilities | 11,864,912 | 1,026,496 | 164,752 | 13,056,160 | |||||||||||||
Redeemable OP unitholder and noncontrolling interests | 163,080 | — | 79,959 | (H) | 243,039 | ||||||||||||
Commitments and contingencies | |||||||||||||||||
Equity: | |||||||||||||||||
Total Ventas stockholders' equity | 8,548,796 | 1,110,084 | 565,509 | (I) | 10,224,389 | ||||||||||||
Noncontrolling interest | 74,377 | 11,757 | (11,757 | ) | (J) | 74,377 | |||||||||||
Total equity | 8,623,173 | 1,121,841 | 553,752 | 10,298,766 | |||||||||||||
Total liabilities and equity | .. | $ | 2,148,337 | $ | 798,463 | $ | 23,597,965 | ||||||||||
See accompanying notes to unaudited pro forma condensed consolidated financial statements.
VENTAS, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
For the nine months ended September 30, 2014
(In thousands, except per share amounts)
Ventas Historical | Ventas 2014 Transactions Adjustments (K) | Pro Forma for Ventas 2014 Transactions | HCT Historical (A) | HCT 2014 Transactions Adjustments (K) | Pro Forma for HCT 2014 Transactions | HCT Acquisition Adjustments (B) | Total Pro Forma | ||||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||||
Rental income: | |||||||||||||||||||||||||||||||||
Triple-net leased | $ | 724,778 | $ | 14,295 | $ | 739,073 | $ | 23,562 | $ | 6,294 | $ | 29,856 | $ | 196 | (L) | $ | 769,125 | ||||||||||||||||
Medical office buildings | 346,711 | (209 | ) | 346,502 | 74,076 | 1,776 | 75,852 | (277 | ) | (L) | 422,077 | ||||||||||||||||||||||
1,071,489 | 14,086 | 1,085,575 | 97,638 | 8,070 | 105,708 | (81 | ) | 1,191,202 | |||||||||||||||||||||||||
Resident fees and services | 1,141,781 | 86,675 | 1,228,456 | 96,120 | 19,179 | 115,299 | — | 1,343,755 | |||||||||||||||||||||||||
Medical office building and other services revenue | 18,240 | — | 18,240 | — | — | — | — | 18,240 | |||||||||||||||||||||||||
Income from loans and investments | 39,435 | 2,313 | 41,748 | 986 | — | 986 | (18 | ) | (M) | 42,716 | |||||||||||||||||||||||
Interest and other income | 814 | (2 | ) | 812 | — | — | — | — | 812 | ||||||||||||||||||||||||
Total revenues | 2,271,759 | 103,072 | 2,374,831 | 194,744 | 27,249 | 221,993 | (99 | ) | 2,596,725 | ||||||||||||||||||||||||
Expenses: | |||||||||||||||||||||||||||||||||
Interest | 277,811 | 31,229 | 309,040 | 20,593 | 359 | 20,952 | (4,013 | ) | (N) | 325,979 | |||||||||||||||||||||||
Depreciation and amortization | 585,636 | 45,158 | 630,794 | 93,262 | 12,440 | 105,702 | (25,971 | ) | (O) | 710,525 | |||||||||||||||||||||||
Property-level operating expenses: | |||||||||||||||||||||||||||||||||
Senior living | 762,993 | 43,700 | 806,693 | 69,773 | 12,853 | 82,626 | — | 889,319 | |||||||||||||||||||||||||
Medical office buildings | 119,827 | (39 | ) | 119,788 | 15,713 | 487 | 16,200 | — | 135,988 | ||||||||||||||||||||||||
882,820 | 43,661 | 926,481 | 85,486 | 13,340 | 98,826 | — | 1,025,307 | ||||||||||||||||||||||||||
Medical office building services costs | 9,565 | — | 9,565 | — | — | — | — | 9,565 | |||||||||||||||||||||||||
General, administrative and professional fees | 93,638 | (23 | ) | 93,615 | 6,743 | — | 6,743 | — | 100,358 | ||||||||||||||||||||||||
Loss on extinguishment of debt, net | 5,079 | (243 | ) | 4,836 | — | — | — | — | 4,836 | ||||||||||||||||||||||||
Merger-related expenses and deal costs | 37,108 | (8,893 | ) | 28,215 | 36,144 | (8,159 | ) | 27,985 | — | 56,200 | |||||||||||||||||||||||
Other | 25,321 | — | 25,321 | 69,317 | — | 69,317 | (69,317 | ) | (P) | 25,321 | |||||||||||||||||||||||
Total expenses | 1,916,978 | 110,889 | 2,027,867 | 311,545 | 17,980 | 329,525 | (99,301 | ) | 2,258,091 | ||||||||||||||||||||||||
Income (loss) before income from unconsolidated entities, income taxes, discontinued operations, real estate dispositions and noncontrolling interest | 354,781 | (7,817 | ) | 346,964 | (116,801 | ) | 9,269 | (107,532 | ) | 99,202 | 338,634 | ||||||||||||||||||||||
Income from unconsolidated entities | 549 | (218 | ) | 331 | — | — | — | — | 331 | ||||||||||||||||||||||||
Income tax (expense) benefit | (4,820 | ) | 6,066 | 1,246 | (1,131 | ) | — | (1,131 | ) | 1,102 | (Q) | 1,217 | |||||||||||||||||||||
Income (loss) from continuing operations | 350,510 | (1,969 | ) | 348,541 | (117,932 | ) | 9,269 | (108,663 | ) | 100,304 | 340,182 | ||||||||||||||||||||||
Gain (loss) on real estate dispositions | 16,514 | (17,508 | ) | (994 | ) | — | — | — | — | (994 | ) | ||||||||||||||||||||||
Income (loss) from continuing operations, including real estate dispositions | 367,024 | (19,477 | ) | 347,547 | (117,932 | ) | 9,269 | (108,663 | ) | 100,304 | 339,188 | ||||||||||||||||||||||
Net income (loss) attributable to noncontrolling interest | 964 | 219 | 1,183 | (1,487 | ) | — | (1,487 | ) | 1,487 | (R) | 1,183 | ||||||||||||||||||||||
Income (loss) from continuing operations attributable to common stockholders, including real estate dispositions | $ | 366,060 | $ | (19,696 | ) | $ | 346,364 | $ | (116,445 | ) | $ | 9,269 | $ | (107,176 | ) | $ | 98,817 | $ | 338,005 | ||||||||||||||
Income (loss) from continuing operations attributable to common stockholders per common share, including real estate dispositions: | |||||||||||||||||||||||||||||||||
Basic | $ | 1.24 | $ | — | $ | 1.18 | $ | (0.66 | ) | $ | — | $ | (0.61 | ) | N/A | $ | 1.06 | ||||||||||||||||
Diluted | $ | 1.23 | $ | — | $ | 1.17 | $ | (0.66 | ) | $ | — | $ | (0.61 | ) | N/A | $ | 1.05 | ||||||||||||||||
Weighted average shares used in computing earnings per common share: | |||||||||||||||||||||||||||||||||
Basic | 293,965 | — | 293,965 | 175,234 | — | 175,234 | 25,723 | (S) | 319,688 | ||||||||||||||||||||||||
Diluted | 296,411 | — | 296,411 | 175,234 | — | 175,234 | 26,914 | (S) | 323,325 | ||||||||||||||||||||||||
See accompanying notes to unaudited pro forma condensed consolidated financial statements.
VENTAS, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
For the year ended December 31, 2013
(In thousands, except per share amounts)
Ventas Historical | Ventas 2014 and 2013 Transactions Adjustments (K) | Pro Forma for Ventas 2014 and 2013 Transactions | HCT Historical (A) | HCT 2014 and 2013 Transactions Adjustments (K) | Pro Forma for HCT 2014 and 2013 Transactions | HCT Acquisition Adjustments (B) | Total Pro Forma | ||||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||||
Rental income: | |||||||||||||||||||||||||||||||||
Triple-net leased | $ | 875,877 | $ | 70,099 | $ | 945,976 | $ | 12,880 | $ | 27,926 | $ | 40,806 | $ | 261 | (L) | $ | 987,043 | ||||||||||||||||
Medical office buildings | 450,107 | 5,957 | 456,064 | 64,075 | 35,182 | 99,257 | (306 | ) | (L) | 555,015 | |||||||||||||||||||||||
1,325,984 | 76,056 | 1,402,040 | 76,955 | 63,108 | 140,063 | (45 | ) | 1,542,058 | |||||||||||||||||||||||||
Resident fees and services | 1,406,005 | 198,938 | 1,604,943 | 47,698 | 102,132 | 149,830 | — | 1,754,773 | |||||||||||||||||||||||||
Medical office building and other services revenue | 17,809 | 596 | 18,405 | — | — | — | — | 18,405 | |||||||||||||||||||||||||
Income from loans and investments | 58,208 | (3,233 | ) | 54,975 | 569 | — | 569 | (13 | ) | (M) | 55,531 | ||||||||||||||||||||||
Interest and other income | 2,047 | 1 | 2,048 | 89 | — | 89 | — | 2,137 | |||||||||||||||||||||||||
Total revenues | 2,810,053 | 272,358 | 3,082,411 | 125,311 | 165,240 | 290,551 | (58 | ) | 3,372,904 | ||||||||||||||||||||||||
Expenses: | |||||||||||||||||||||||||||||||||
Interest | 334,484 | 70,127 | 404,611 | 15,843 | 3,978 | 19,821 | 1,453 | (N) | 425,885 | ||||||||||||||||||||||||
Depreciation and amortization | 721,959 | 117,354 | 839,313 | 67,456 | 84,176 | 151,632 | (1,924 | ) | (O) | 989,021 | |||||||||||||||||||||||
Property-level operating expenses: | |||||||||||||||||||||||||||||||||
Senior living | 956,684 | 104,957 | 1,061,641 | 33,151 | 64,703 | 97,854 | — | 1,159,495 | |||||||||||||||||||||||||
Medical office buildings | 152,948 | 3,069 | 156,017 | 12,814 | 6,132 | 18,946 | — | 174,963 | |||||||||||||||||||||||||
1,109,632 | 108,026 | 1,217,658 | 45,965 | 70,835 | 116,800 | — | 1,334,458 | ||||||||||||||||||||||||||
Medical office building services costs | 8,315 | — | 8,315 | — | — | — | — | 8,315 | |||||||||||||||||||||||||
General, administrative and professional fees | 115,106 | (22 | ) | 115,084 | 4,089 | — | 4,089 | — | 119,173 | ||||||||||||||||||||||||
Loss on extinguishment of debt, net | 1,201 | 243 | 1,444 | — | — | — | — | 1,444 | |||||||||||||||||||||||||
Merger-related expenses and deal costs | 21,634 | (7,276 | ) | 14,358 | 13,606 | (15,239 | ) | (1,633 | ) | — | 12,725 | ||||||||||||||||||||||
Other | 18,732 | — | 18,732 | — | — | — | — | 18,732 | |||||||||||||||||||||||||
Total expenses | 2,331,063 | 288,452 | 2,619,515 | 146,959 | 143,750 | 290,709 | (471 | ) | 2,909,753 | ||||||||||||||||||||||||
Income (loss) before loss from unconsolidated entities, income taxes, discontinued operations, real estate dispositions and noncontrolling interest | 478,990 | (16,094 | ) | 462,896 | (21,648 | ) | 21,490 | (158 | ) | 413 | 463,151 | ||||||||||||||||||||||
Loss from unconsolidated entities | (508 | ) | 493 | (15 | ) | — | — | — | — | (15 | ) | ||||||||||||||||||||||
Income tax benefit (expense) | 11,828 | 10,691 | 22,519 | (524 | ) | — | (524 | ) | 17,296 | (Q) | 39,291 | ||||||||||||||||||||||
Income (loss) from continuing operations | 490,310 | (4,910 | ) | 485,400 | (22,172 | ) | 21,490 | (682 | ) | 17,709 | 502,427 | ||||||||||||||||||||||
Gain on real estate dispositions | — | 17,508 | 17,508 | — | — | — | — | 17,508 | |||||||||||||||||||||||||
Income (loss) from continuing operations, including real estate dispositions | 490,310 | 12,598 | 502,908 | (22,172 | ) | 21,490 | (682 | ) | 17,709 | 519,935 | |||||||||||||||||||||||
Net income attributable to noncontrolling interest | 1,380 | 465 | 1,845 | 58 | — | 58 | (58 | ) | (R) | 1,845 | |||||||||||||||||||||||
Income (loss) from continuing operations attributable to common stockholders | $ | 488,930 | $ | 12,133 | $ | 501,063 | $ | (22,230 | ) | $ | 21,490 | $ | (740 | ) | $ | 17,767 | $ | 518,090 | |||||||||||||||
Income (loss) from continuing operations attributable to common stockholders per common share, including real estate dispositions: | |||||||||||||||||||||||||||||||||
Basic | $ | 1.67 | $ | — | $ | 1.71 | $ | (0.15 | ) | $ | — | $ | (0.00 | ) | N/A | $ | 1.63 | ||||||||||||||||
Diluted | $ | 1.66 | $ | — | $ | 1.70 | $ | (0.15 | ) | $ | — | $ | (0.00 | ) | N/A | $ | 1.61 | ||||||||||||||||
Weighted average shares used in computing earnings per common share: | |||||||||||||||||||||||||||||||||
Basic | 292,654 | — | 292,654 | 151,684 | — | 151,684 | 25,723 | (S) | 318,377 | ||||||||||||||||||||||||
Diluted | 295,110 | — | 295,110 | 151,684 | — | 151,684 | 26,914 | (S) | 322,024 | ||||||||||||||||||||||||
See accompanying notes to unaudited pro forma condensed consolidated financial statements.
VENTAS, INC.
NOTES AND MANAGEMENT’S ASSUMPTIONS TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1 - BASIS OF PRO FORMA PRESENTATION
Ventas, Inc. (“Ventas” or the “Company”) is a real estate investment trust (“REIT”) with a geographically diverse portfolio of seniors housing and healthcare properties in the United States, Canada and the United Kingdom. The historical consolidated financial statements of Ventas include the accounts of the Company and its wholly owned subsidiaries and joint venture entities over which it exercises control.
On June 2, 2014, Ventas announced that it had entered into a definitive agreement to acquire all of the outstanding shares of American Realty Capital Healthcare Trust, Inc. (“HCT”) in a stock and cash transaction valued at $2.9 billion, or $11.33 per HCT share, including investments expected to be made by HCT prior to the acquisition, substantially all of which have now been completed.
NOTE 2 - ADJUSTMENTS TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
(A) Reflects historical consolidated financial condition or results of operations of HCT as of or for the nine months ended September 30, 2014 or for the year ended December 31, 2013. Certain amounts have been reclassified to conform to Ventas’s presentation.
(B) Reflects adjustments to record the acquisition of HCT by Ventas based upon the estimated purchase price of approximately $2.9 billion. The calculation of the estimated purchase price to be allocated is as follows (in millions, except per share amounts):
Equity to be issued (26.9 million shares at $67.13 per share) | $ | 1,806 | |
Cash to be paid (assumed to be funded with borrowings under Ventas’s unsecured revolving credit facility) | 192 | ||
Assumption or repayment of net debt | 930 | ||
Estimated purchase price | $ | 2,928 | |
(C) Reflects adjustment to record the estimated increase over HCT’s historical investment in real estate based upon the preliminary estimated fair value for the tangible and intangible real estate assets to be acquired. These estimated values are as follows (in millions):
Land and improvements | $ | 333 | ||
Buildings and improvements | 2,174 | |||
Acquired lease intangibles | 215 | |||
Estimated fair value of net real estate investments | $ | 2,722 | ||
(D) Reflects the write-off of HCT’s historical deferred financing costs, which were not assigned any value in the preliminary purchase price allocation.
(E) Reflects adjustments to eliminate assets of HCT included in the historical consolidated financial information that Ventas is not acquiring as part of the working capital consideration, net of other acquired assets, primarily consisting of approximately $150 million of other intangible assets.
(F) Reflects the following adjustments (in millions):
Write-off of HCT’s historical fair value of debt adjustments | $ | (4 | ) | |
Fair value of debt adjustment recorded in connection with the acquisition | 11 | |||
HCT debt anticipated to be repaid at closing | (620 | ) | ||
Anticipated borrowings under Ventas’s unsecured revolving credit facility | 812 | |||
Pro forma adjustment to debt | $ | 199 | ||
(G) Reflects adjustments to eliminate historical other liabilities of HCT that were not assigned any value in the preliminary purchase price allocation and the recording of approximately $32 million of various lease intangibles, which were recorded based on preliminary fair value calculations.
(H) Reflects the adjustment to record the fair value of the redeemable OP unitholder interests, which are valued at a price of $11.33 per unit (the acquisition value of each share of HCT common stock at the time the acquisition was announced).
(I) Reflects the write-off of HCT’s historical equity, net of the issuance of 26.9 million shares of Ventas common stock in connection with the HCT acquisition, which are valued at $1.8 billion.
(J) Reflects the adjustment to record the reclassification of HCT’s historical noncontrolling interest value to redeemable OP unitholder interests.
NOTE 3 - ADJUSTMENTS TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(K) Adjustments reflect the effect on Ventas’s and HCT’s historical consolidated statements of income of Ventas’s and HCT’s respective significant 2014 and 2013 transactions, as if those transactions were consummated on January 1, 2013. With respect to Ventas, these adjustments primarily relate to certain acquisitions and dispositions (including its August 2014 acquisition of 29 independent living seniors housing communities located in Canada) and debt repayments and issuances. With respect to HCT, these adjustments primarily relate to various asset acquisitions. Adjustments made to merger-related expenses and deal costs reflect the elimination of non-recurring expenses resulting from Ventas’s and HCT’s 2014 and 2013 acquisitions that are assumed, for purposes of these unaudited pro forma condensed consolidated financial statements, to have occurred on January 1, 2013. Such expenses include legal and professional fees, title insurance fees, recording fees and certain taxes, none of which is considered material individually or in the aggregate.
(L) Reflects the net amortization of above and below market lease intangibles recorded by Ventas as a result of the HCT acquisition and the elimination of HCT’s historical amortization related to above and below market lease intangibles.
(M) Reflects the elimination of HCT’s historical revenues attributable to assets that Ventas is not acquiring as part of the acquisition.
(N) Reflects the following adjustments (in millions):
For the Nine Months Ended September 30, 2014 | For the Year Ended December 31, 2013 | |||||||
Write-off of HCT’s historical fair value of debt adjustments | $ | 1 | $ | 1 | ||||
Fair value of debt adjustment recorded in connection with the acquisition | (2 | ) | (4 | ) | ||||
HCT debt anticipated to be repaid at closing | (5 | ) | (1 | ) | ||||
Anticipated borrowings under Ventas’s unsecured revolving credit facility | 7 | 10 | ||||||
Write-off of HCT’s deferred financing costs | (5 | ) | (4 | ) | ||||
Pro forma adjustment to interest expense | $ | (4 | ) | $ | 2 | |||
(O) Based on the preliminary purchase price allocation, Ventas expects to allocate $333 million to land and $2.2 billion to buildings and improvements. Depreciation expense is calculated on a straight-line basis based on Ventas’s purchase price allocation and using a 35-year life for buildings and permanent structural improvements, a five-year life for furniture and equipment and a ten-year life for land improvements. Additionally, Ventas’s purchase price allocation includes $180 million of acquired in-place lease intangibles. Further, the adjustment reflects the elimination of historical depreciation and amortization expense relating to the merger, as follows (in thousands):
HCT Acquisition Adjustments | ||||||||||
Weighted Average Useful Life (Years) | For the Nine Months Ended September 30, 2014 | For the Year Ended December 31, 2013 | ||||||||
Elimination of HCT’s historical and pro forma depreciation and amortization | N/A | $ | (105,702 | ) | $ | (151,632 | ) | |||
Ventas’s HCT Acquisition Adjustments for depreciation and amortization, by asset type: | ||||||||||
Site improvements | 9.1 | 6,647 | 8,863 | |||||||
Building and improvements | 33.4 | 52,185 | 69,580 | |||||||
Furniture and equipment | 5.0 | 4,878 | 6,504 | |||||||
In-place lease intangibles | 6.3 | 16,021 | 64,761 | |||||||
Total | N/A | 79,731 | 149,708 | |||||||
Adjustment for depreciation and amortization | N/A | $ | (25,971 | ) | $ | (1,924 | ) | |||
(P) Reflects the elimination of costs and fees directly attributable to the merger and fees associated with the ultimate disposition of HCT’s assets. The $69.3 million adjustment represents (i) a $56.4 million fair value adjustment of the Listing Note (as disclosed in Note 10 to HCT’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014), and (ii) $12.9 million of asset management expenses paid by HCT to a related party (as disclosed in Note 15 to HCT’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014).
(Q) Reflects adjustment to eliminate the historical tax expense of HCT, offset by the estimated tax benefit Ventas expects to recognize due to the acquisition.
(R) Reflects the elimination of HCT’s noncontrolling interest that Ventas is not acquiring as part of the acquisition.
(S) Reflects the issuance of 26.9 million shares of Ventas common stock upon consummation of the HCT acquisition, including the impact of redeemable OP units issued on the acquisition date.
NOTE 4 - FUNDS FROM OPERATIONS AND NORMALIZED FUNDS FROM OPERATIONS
Ventas’s historical and pro forma funds from operations (“FFO”) and normalized FFO for the nine months ended September 30, 2014 and the year ended December 31, 2013 are summarized as follows (in thousands):
VENTAS, INC.
UNAUDITED PRO FORMA FFO AND NORMALIZED FFO
For the nine months ended September 30, 2014
(In thousands, except per share amounts)
Ventas Historical | Ventas 2014 Transactions Adjustments | Pro Forma for Ventas 2014 Transactions | HCT Historical | HCT 2014 Transactions Adjustments | Pro Forma for HCT 2014 Transactions | HCT Acquisition Adjustments | Total Pro Forma | ||||||||||||||||||||||||
Income (loss) from continuing operations attributable to common stockholders, including real estate dispositions | $ | 366,060 | $ | (19,696 | ) | $ | 346,364 | $ | (116,445 | ) | $ | 9,269 | $ | (107,176 | ) | $ | 98,817 | $ | 338,005 | ||||||||||||
Discontinued operations | 2,517 | (3,738 | ) | (1,221 | ) | — | — | — | — | (1,221 | ) | ||||||||||||||||||||
Net income (loss) attributable to common stockholders | 368,577 | (23,434 | ) | 345,143 | (116,445 | ) | 9,269 | (107,176 | ) | 98,817 | 336,784 | ||||||||||||||||||||
Adjustments: | |||||||||||||||||||||||||||||||
Real estate depreciation and amortization | 580,879 | 45,158 | 626,037 | 93,077 | 12,440 | 105,517 | (25,971 | ) | 705,583 | ||||||||||||||||||||||
Real estate depreciation related to noncontrolling interest | (7,808 | ) | — | (7,808 | ) | — | — | — | — | (7,808 | ) | ||||||||||||||||||||
Real estate depreciation related to unconsolidated entities | 4,460 | — | 4,460 | — | — | — | — | 4,460 | |||||||||||||||||||||||
(Gain) loss on real estate dispositions | (16,514 | ) | 17,508 | 994 | — | — | — | — | 994 | ||||||||||||||||||||||
Discontinued operations: | |||||||||||||||||||||||||||||||
Gain on real estate dispositions | (1,442 | ) | 1,037 | (405 | ) | — | — | — | — | (405 | ) | ||||||||||||||||||||
Depreciation on real estate assets | 1,540 | (352 | ) | 1,188 | — | — | — | — | 1,188 | ||||||||||||||||||||||
FFO | 929,692 | 39,917 | 969,609 | (23,368 | ) | 21,709 | (1,659 | ) | 72,846 | 1,040,796 | |||||||||||||||||||||
Adjustments: | |||||||||||||||||||||||||||||||
Change in fair value of financial instruments | 4,636 | — | 4,636 | — | — | — | — | 4,636 | |||||||||||||||||||||||
Non-cash income tax expense (benefit) | 4,420 | (6,066 | ) | (1,646 | ) | 1,131 | — | 1,131 | (1,102 | ) | (1,617 | ) | |||||||||||||||||||
Loss on extinguishment of debt, net | 4,528 | (243 | ) | 4,285 | — | — | — | — | 4,285 | ||||||||||||||||||||||
Merger-related expenses, deal costs and re-audit costs | 43,764 | (8,893 | ) | 34,871 | 36,144 | (8,159 | ) | 27,985 | — | 62,856 | |||||||||||||||||||||
Amortization of other intangibles | 766 | — | 766 | — | — | — | — | 766 | |||||||||||||||||||||||
Normalized FFO | $ | 987,806 | $ | 24,715 | $ | 1,012,521 | $ | 13,907 | $ | 13,550 | $ | 27,457 | $ | 71,744 | $ | 1,111,722 | |||||||||||||||
Ventas’s historical and pro forma FFO and normalized FFO per diluted share outstanding for the nine months ended September 30, 2014 follows (in thousands, except per share amounts) (1):
Ventas Historical | Total Pro Forma | ||||||
Income from continuing operations attributable to common stockholders, including real estate dispositions | $ | 1.23 | $ | 1.05 | |||
Discontinued operations | 0.01 | (0.00 | ) | ||||
Net income attributable to common stockholders | 1.24 | 1.04 | |||||
Adjustments: | |||||||
Real estate depreciation and amortization | 1.96 | 2.18 | |||||
Real estate depreciation related to noncontrolling interest | (0.03 | ) | (0.02 | ) | |||
Real estate depreciation related to unconsolidated entities | 0.02 | 0.01 | |||||
(Gain) loss on real estate dispositions | (0.06 | ) | 0.00 | ||||
Discontinued operations: | |||||||
Gain on real estate dispositions | (0.00 | ) | (0.00 | ) | |||
Depreciation on real estate assets | 0.01 | 0.00 | |||||
FFO | 3.14 | 3.22 | |||||
Adjustments: | |||||||
Change in fair value of financial instruments | 0.02 | 0.01 | |||||
Non-cash income tax expense (benefit) | 0.01 | (0.01 | ) | ||||
Loss on extinguishment of debt, net | 0.02 | 0.01 | |||||
Merger-related expenses, deal costs and re-audit costs | 0.15 | 0.19 | |||||
Amortization of other intangibles | 0.00 | 0.00 | |||||
Normalized FFO | $ | 3.33 | $ | 3.44 | |||
Dilutive shares outstanding used in computing FFO and normalized FFO per common share | 296,411 | 323,325 | |||||
(1) Per share amounts may not add due to rounding.
VENTAS, INC.
UNAUDITED PRO FORMA FFO AND NORMALIZED FFO
For the year ended December 31, 2013
(In thousands, except per share amounts)
Ventas Historical | Ventas 2014 and 2013 Transactions Adjustments | Pro Forma for Ventas 2014 and 2013 Transactions | HCT Historical | HCT 2014 and 2013 Transactions Adjustments | Pro Forma for HCT 2014 and 2013 Transactions | HCT Acquisition Adjustments | Total Pro Forma | ||||||||||||||||||||||||
Income (loss) from continuing operations attributable to common stockholders, including real estate dispositions | $ | 488,930 | $ | 12,133 | $ | 501,063 | $ | (22,230 | ) | $ | 21,490 | $ | (740 | ) | $ | 17,767 | $ | 518,090 | |||||||||||||
Discontinued operations | (35,421 | ) | 3,069 | (32,352 | ) | — | — | — | — | (32,352 | ) | ||||||||||||||||||||
Net income (loss) attributable to common stockholders | 453,509 | 15,202 | 468,711 | (22,230 | ) | 21,490 | (740 | ) | 17,767 | 485,738 | |||||||||||||||||||||
Adjustments: | |||||||||||||||||||||||||||||||
Real estate depreciation and amortization | 716,412 | 117,354 | 833,766 | 66,975 | 84,176 | 151,151 | (1,924 | ) | 982,993 | ||||||||||||||||||||||
Real estate depreciation related to noncontrolling interest | (10,512 | ) | — | (10,512 | ) | — | — | — | — | (10,512 | ) | ||||||||||||||||||||
Real estate depreciation related to unconsolidated entities | 6,543 | — | 6,543 | — | — | — | — | 6,543 | |||||||||||||||||||||||
Gain on re-measurement of equity interest upon acquisition, net | (1,241 | ) | — | (1,241 | ) | — | — | — | — | (1,241 | ) | ||||||||||||||||||||
Gain on real estate dispositions | — | (17,508 | ) | (17,508 | ) | — | — | — | — | (17,508 | ) | ||||||||||||||||||||
Discontinued operations: | |||||||||||||||||||||||||||||||
Gain on real estate dispositions | (4,059 | ) | (1,241 | ) | (5,300 | ) | — | — | — | — | (5,300 | ) | |||||||||||||||||||
Depreciation on real estate assets | 47,806 | (9,066 | ) | 38,740 | — | — | — | — | 38,740 | ||||||||||||||||||||||
FFO | 1,208,458 | 104,741 | 1,313,199 | 44,745 | 105,666 | 150,411 | 15,843 | 1,479,453 | |||||||||||||||||||||||
Adjustments: | |||||||||||||||||||||||||||||||
Change in fair value of financial instruments | 449 | — | 449 | — | — | — | — | 449 | |||||||||||||||||||||||
Non-cash income tax (benefit) expense | (11,828 | ) | (10,691 | ) | (22,519 | ) | 524 | — | 524 | (17,296 | ) | (39,291 | ) | ||||||||||||||||||
Loss on extinguishment of debt, net | 1,048 | 243 | 1,291 | — | — | — | — | 1,291 | |||||||||||||||||||||||
Merger-related expenses, deal costs and re-audit fees | 21,560 | (7,276 | ) | 14,284 | 13,606 | (15,239 | ) | (1,633 | ) | — | 12,651 | ||||||||||||||||||||
Amortization of other intangibles | 1,022 | — | 1,022 | — | — | — | — | 1,022 | |||||||||||||||||||||||
Normalized FFO | $ | 1,220,709 | $ | 87,017 | $ | 1,307,726 | $ | 58,875 | $ | 90,427 | $ | 149,302 | $ | (1,453 | ) | $ | 1,455,575 | ||||||||||||||
Ventas’s historical and pro forma FFO and normalized FFO per diluted share outstanding for the year ended December 31, 2013 follows (in thousands, except per share amounts) (1):
Ventas Historical | Total Pro Forma | ||||||
Income from continuing operations attributable to common stockholders, including real estate dispositions | $ | 1.66 | $ | 1.61 | |||
Discontinued operations | (0.12 | ) | (0.10 | ) | |||
Net income attributable to common stockholders | 1.54 | 1.51 | |||||
Adjustments: | |||||||
Real estate depreciation and amortization | 2.43 | 3.05 | |||||
Real estate depreciation related to noncontrolling interest | (0.04 | ) | (0.03 | ) | |||
Real estate depreciation related to unconsolidated entities | 0.02 | 0.02 | |||||
Gain on re-measurement of equity interest upon acquisition, net | (0.00 | ) | (0.00 | ) | |||
Gain on real estate dispositions | — | (0.05 | ) | ||||
Discontinued operations: | |||||||
Gain on real estate dispositions | (0.01 | ) | (0.02 | ) | |||
Depreciation on real estate assets | 0.16 | 0.12 | |||||
FFO | 4.09 | 4.59 | |||||
Adjustments: | |||||||
Change in fair value of financial instruments | 0.00 | 0.00 | |||||
Non-cash income tax benefit | (0.04 | ) | (0.12 | ) | |||
Loss on extinguishment of debt, net | 0.00 | 0.00 | |||||
Merger-related expenses, deal costs and re-audit costs | 0.07 | 0.04 | |||||
Amortization of other intangibles | 0.00 | 0.00 | |||||
Normalized FFO | $ | 4.14 | $ | 4.52 | |||
Dilutive shares outstanding used in computing FFO and normalized FFO per common share | 295,110 | 322,024 | |||||
(1) Per share amounts may not add due to rounding.
Unaudited pro forma FFO and normalized FFO are presented herein for informational purposes only and are based on available information and assumptions that the Company’s management believes to be reasonable; however, they are not necessarily indicative of what Ventas’s FFO or normalized FFO actually would have been assuming the transactions had occurred as of the dates indicated.
Historical cost accounting for real estate assets implicitly assumes that the value of real estate assets diminishes predictably over time. However, since real estate values historically have risen or fallen with market conditions, many industry investors deem presentations of operating results for real estate companies that use historical cost accounting to be insufficient by themselves. To overcome this problem, Ventas considers FFO and normalized FFO to be appropriate measures of operating performance of an equity REIT. In particular, Ventas believes that normalized FFO is useful because it allows investors, analysts and Ventas management to compare Ventas’s operating performance to the operating performance of other real estate companies and between periods on a consistent basis without having to account for differences caused by unanticipated items and other events such as transactions and litigation. In some cases, Ventas provides information about identified non-cash components of FFO and normalized FFO because it allows investors, analysts and Ventas management to assess the impact of those items on Ventas’s financial results.
Ventas uses the National Association of Real Estate Investment Trusts (“NAREIT”) definition of FFO. NAREIT defines FFO as net income (computed in accordance with GAAP), excluding gains (or losses) from sales of real estate property, including gain on re-measurement of equity method investments, and impairment write-downs of depreciable real estate, plus real estate depreciation and amortization, and after adjustments for unconsolidated partnerships and joint ventures. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect FFO on the same basis. Ventas defines normalized FFO as FFO excluding the following income and expense items (which may be recurring in nature): (a) merger-related costs and expenses, including amortization of intangibles, transition and integration expenses, and deal costs and expenses, including expenses and recoveries relating to the Company’s acquisition lawsuits; (b) the impact of any expenses related to asset impairment and valuation allowances, the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of the Company’s debt; (c) the non-cash effect of income tax benefits or expenses and derivative transactions that have non-cash mark-to-market impacts on the Company’s consolidated statements of income; (d) the impact of future acquisitions or divestitures (including pursuant to tenant options to purchase) and capital transactions; (e) the financial impact of contingent consideration, severance-related costs, charitable donations made to the Ventas Charitable Foundation, gains and losses for non-operational foreign currency hedge agreements and changes in the fair value of financial instruments; and (f) expenses related to the re-audit and re-review of the Company’s historical financial statements and related matters.
FFO and normalized FFO presented herein may not be identical to FFO and normalized FFO presented by other real estate companies due to the fact that not all real estate companies use the same definitions. FFO and normalized FFO should not be considered as alternatives to net income (determined in accordance with GAAP) as indicators of Ventas’s financial performance or as alternatives to cash flow from operating activities (determined in accordance with GAAP) as measures of Ventas’s liquidity, nor is FFO and normalized FFO necessarily indicative of sufficient cash flow to fund all of Ventas’s needs. Ventas believes that in order to facilitate a clear understanding of Ventas’s consolidated historical operating results, FFO and normalized FFO should be examined in conjunction with net income as presented in the unaudited pro forma condensed consolidated financial statements.